Related Experiment Videos
Insights
Certain children with brainstem gliomas may survive long-term, even without aggressive treatment. Identifying favorable prognostic factors like neurofibromatosis can help predict survival in pediatric brain tumor patients.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Childhood Brain Tumors
Background:
- Brainstem gliomas in children typically have a poor prognosis, with median survival rates of 9-12 months.
- Despite the grim outlook, a subset of long-term survivors exists, suggesting potential for better outcomes in specific cases.
Purpose of the Study:
- To identify potential prognostic factors associated with long-term survival in pediatric brainstem gliomas.
- To inform the development of new treatment strategies by understanding survival variations.
Main Methods:
- Retrospective analysis of 12 pediatric patients diagnosed with brainstem gliomas.
- Evaluation of clinical, radiological (CT scan), and pathological data to identify survival predictors.
Main Results:
- Five out of 12 patients survived beyond 6 years; six survived 12 months or less.
- One patient survived 3 years, also considered in the long-term survivor group.
- Favorable prognostic indicators included neurofibromatosis, symptom duration >= 12 months, tumor calcification on CT, exophytic location, and low-grade pathology.
Conclusions:
- Pediatric brainstem glioma patients can experience prolonged survival, sometimes without intensive treatment.
- Prognostic factors such as neurofibromatosis and specific tumor characteristics are crucial for identifying patients with better survival potential.
- These findings necessitate consideration of patient subgroups when designing novel therapeutic regimens for brainstem gliomas.
Abstract:
Although brainstem gliomas carry the worst prognosis of any brain tumor in children, with median survivals of 9 to 12 months, there may be a subgroup of long-term survivors. We have identified 12 children with brainstem gliomas, 5 of whom have survived greater than 6 years and 6 less than or equal to 12 months. Another child, alive and well 3 years following diagnosis, was considered in the long-term survivor group. Favorable prognostic factors included neurofibromatosis, symptoms greater than or equal to 12 months before diagnosis, calcification on CT, exophytic location, and pathology suggesting a low-grade tumor. Recognition that certain patients with brainstem gliomas may have prolonged survivals even in the absence of definitive treatment must be taken into consideration when new treatment regimens are being formulated.